Supplemental Figure S1. Structures of PAR4 antagonists VU0652925 and VU0661245.



VU0652925



VU0661245

Supplemental Figure S2. Inhibition of thrombin-mediated platelet activation by PAR4 antagonists VU0652925 and VU0661245. Platelets were pre-treated with increasing concentrations (shown in log scale) of VU0652925 or VU0661245 for 20 minutes before activation with 100 nM or 316 nM γ-thrombin. Platelet activation was measured as integrin αIIbβ3 inside-out activation (PAC1 expression) by flow cytometry. Data are normalized to vehicle control and displayed as means ± S.E.M.; n = 3.





Supplemental Figure S3. Ultrastructural analysis of granulocyte-platelet interactions from purified isolates. Washed human platelets (20×10^7/ml) and purified granulocytes (20×10^6/ml) from the same donor were combined and activated with human α-thrombin (5 nM = 0.7 U/ml) before preparation for electron microscopy. Granulocytes were identified by characteristic ultrastructural features. (A-B) Platelets (arrows) are shown interacting with one granulocyte in each image. Interactions show characteristic molding of surface morphology and cohesion. Scale bar for each panel = 1 μm.